查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1445540

全球前列腺癌活檢市場評估：按產品類型、指南、最終用戶和地區劃分的機會和預測（2017-2031）

Prostate Cancer Biopsy Market Assessment, By Type, By Product, By Guidance, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5個工作天內

價格

全球前列腺癌活檢市場規模將從 2023 年的 60.9 億美元增長到 2031 年的 110.6 億美元，2024-2031 年預測期內複合年增長率為 7.74%。預計將增長至 .

影響全球前列腺癌活檢市場的因素包括使用人工智慧工具進行前列腺癌活檢、政府舉措、對試劑盒的需求不斷增加、前列腺液體活檢日益普及、MRI 引導等。其中包括採用更安全的導引設備。

全球前列腺癌活檢市場受到幾個關鍵因素的影響，這些因素反映了不斷發展的醫療技術和不斷發展的醫療保健實踐。 提高癌症識別準確性和有效性的一項顯著進展是在前列腺癌活檢中使用人工智慧技術。 人工智慧系統可以準確分析切片影像，改善患者治療結果，並減少誤診機會。

透過使用人工智慧工具增加需求

全球前列腺癌切片的銷售急劇成長，這主要歸功於技術進步，尤其是人工智慧技術的使用。 這些人工智慧技術透過提高活檢過程的準確性和一致性，正在徹底改變前列腺癌的診斷。 人工智慧系統能夠分析複雜的活檢影像並偵測人眼可能錯過的模式和訊號。

透過減少假陰性的機會並提高惡性細胞的檢出率，患者可以得到準確的早期診斷。 將人工智慧納入前列腺癌活檢程序代表了腫瘤學的重大進步，並將改善全球前列腺癌人口數量，因為它可以提供更有效、更準確、侵入性更小的方法來識別前列腺癌。這有望刺激增長和創新在檢驗市場。

政府措施

世界各國政府正在積極推動前列腺癌宣傳活動和篩檢計劃，這為全球前列腺癌活檢市場的成長提供了重要推動力。 這些計劃對於早期發現、提高治療效果和生存機會至關重要。 各國政府支持和促進前列腺癌篩檢計劃，鼓勵男性接受活檢等早期診斷測試。 透過使更多的人在疾病的早期階段得到診斷和治療，這些措施將有助於降低與前列腺癌相關的死亡率，並刺激全球前列腺癌活檢市場。

套件需求增加

對活檢試劑盒的需求不斷增長是全球前列腺癌活檢市場顯著增長的原因。 這些試劑盒在診斷前列腺癌所需的活檢中發揮重要作用。 向微創診斷技術的轉變可提高便利性、患者舒適度和依從性，從而導致需求增加。 活檢套件簡化了醫療保健專業人員的流程，並確保成功、快速地進行活檢。

攝護腺液體切片檢查日益普及

前列腺液體活檢在全球前列腺癌活檢市場中越來越受歡迎，代表著向非侵入性診斷技術的重大轉變。 透過分析患者血液中的循環腫瘤細胞和腫瘤 DNA 片段，液體活檢提供了比標準組織活檢侵入性更小的選擇。 液體活檢正在廣泛接受，因為它們可以早期發現癌症、追蹤其進展並評估治療效果。

本報告調查了全球前列腺癌活檢市場，提供市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。分析、案例研究、競爭格局、以及主要公司的簡介。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球前列腺癌切片市場展望

  • 市場規模/預測
  • 依類型
    • 前列腺液體活檢
    • 前列腺穿刺活檢
  • 按產品
    • 針
    • 套件托盤
    • 其他
  • 透過指導
    • MRI引導的攝護腺切片裝置
    • CT引導攝護腺切片裝置
    • 超音波引導攝護腺切片裝置
    • 其他
  • 按最終用戶
    • 醫院
    • 診斷中心
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率

第 5 章全球前列腺癌切片市場展望：按地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東/非洲

第 6 章市場映射

  • 依類型
  • 按產品
  • 透過指導
  • 按最終用戶
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 10 章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家參與公司）
  • 專利分析（如果適用）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc
  • Koninklijke Philips N.V.
  • Biocept Inc
  • Angle plc
  • Eisai Co., Ltd.
  • Onconetix, Inc.
  • StageZero Life Sciences Ltd

第 14 章策略建議

第 15 章關於我們公司/免責聲明

Product Code: MX11089

Global prostate cancer biopsy market is projected to witness a CAGR of 7.74% during the forecast period 2024-2031, growing from USD 6.09 billion in 2023 to USD 11.06 billion in 2031. Factors that shape the global prostate cancer biopsy market include the use of AI tools for prostate cancer biopsies, government initiatives, increased demand for kits, the growing popularity of prostate liquid biopsy and the adoption of safer guidance devices such as MRI-guidance.

The global prostate cancer biopsy market is influenced by several important factors, which are the reflection of evolving medical technology and evolving healthcare practices. One notable development that improves the accuracy and effectiveness of cancer identification is the use of AI techniques in prostate cancer biopsies. AI systems can accurately analyze biopsy images, improving patient outcomes and reducing the likelihood of a misdiagnosis.

In the global prostate cancer biopsy market, government initiatives that provide funding and assistance for developments in cancer diagnosis are crucial to the progress of the field's research and development. The two main objectives of these projects are raising awareness and improving accessibility of enhanced diagnostic instruments.

Additionally, the growing incidence of prostate cancer is driving the demand for biopsy kits, which in turn is propelling the growth of the global prostate cancer biopsy market. These kits make the biopsy process more patient-friendly by enabling less intrusive treatments and providing convenience. Another development is the increasing prevalence of liquid biopsies of the prostate. By analyzing cancer cell DNA in the blood, liquid biopsies provide a non-invasive substitute for traditional tissue biopsies while providing vital tumor information.

Consequently, the precision of biopsies has increased with the use of safer guidance tools, including MRI-guided biopsy devices. With improved visualization of prostate gland made possible by MRI guidance, suspicious regions can be sampled more precisely, reducing biopsy risks. Together, these elements influence the dynamics of the global prostate cancer biopsy market for prostate cancer biopsies, suggesting ways to enhance patient care and diagnostic options.

Philips and imaging biomarker specialist Quibim partnered in October 2023 to introduce the next generation of AI-based imaging and reporting solutions for MR prostate exams. Combining Quibim's AI-enabled image analysis software with Philips' allows physicians to treat prostate cancer patients more quickly and effectively while reducing costs and staffing shortages.

Use of AI Tools to Expand the Demand

Prostate cancer biopsy sales are rising dramatically worldwide, mostly because of advances in technology, especially the use of AI techniques. These artificial intelligence technologies are improving the accuracy and consistency of biopsy processes, which is revolutionizing the diagnosis of prostate cancer. Artificial intelligence systems possess the ability to analyze intricate biopsy images and detect patterns and signals which human eye would overlook.

Reducing the possibility of false negative results and raising the detection rate of malignant cells guarantees that patients obtain accurate and early diagnoses. By providing a more effective, precise, and minimally invasive method of identifying prostate cancer, the incorporation of AI into prostate cancer biopsy procedures marks a significant advancement in oncology and spurs growth and innovation in the global prostate cancer biopsy market.

For instance, a Florida-based medical technology company introduced a cutting-edge AI diagnostic for prostate cancer treatment in April 2023. Doctors are assisted in selecting individualized patient care by ArteraAI's "first-ever predictive test." Patients with localized prostate cancer benefit from being the first of its kind.

Government Initiatives

Prostate cancer awareness campaigns and screening programs are actively promoted by governments across the globe, which has greatly fueled the expansion of the global prostate cancer biopsy market. These programs are essential for early detection and enhance the effectiveness of treatment and their likelihood of survival. Governments encourage men to undergo early diagnostic tests, such as biopsies, by supporting and promoting prostate cancer screening programs. It increases the demand for biopsy procedures and related technology. By ensuring that more people are diagnosed and treated in the early stages of the disease, such initiatives contribute to lowering the death rate related to prostate cancer and stimulate the global prostate cancer biopsy market.

For instance, on 19th November 2023, The United Kingdom Government initiated a significant prostate cancer screening experiment. A screening trial was announced by Prostate Cancer UK and the Government to find ways to diagnose prostate cancer proactively. Thousands of men who are more likely to get cancer were recruited by them. The trial, named TRANSFORM, will use innovative techniques such as magnetic resonance imaging (MRI) screening to discover cases not detected by blood testing and in the absence of cancer symptoms.

Increased Demand for Kits

The growing need for biopsy kits is behind the significant expansion of global prostate cancer biopsy market. These kits play a crucial role in biopsies, which are necessary for the diagnosis of prostate cancer. Their convenience and the move to less invasive diagnostic techniques, which improve patient comfort and compliance, are credited with their increased demand. Biopsy kits facilitate the process for medical professionals, guaranteeing the successful and rapid execution of biopsies. The pattern is part of a larger shift in healthcare that is patient-centric and emphasizes reducing discomfort and increasing diagnostic precision. The global prostate cancer biopsy market is expected to grow significantly as the awareness and prevalence of prostate cancer increase, leading to a rise in demand for these kits.

Co-labeled digital PCR kits are marketed by Stilla Technologies and Atila Biosystems started in March 2023. "naica" is Stilla's primary PCR device, and the kits and assays are made by Atila. The purpose of these digital PCR kits is to identify circulating tumor DNA (ctDNA) in liquid biopsy samples. These samples are obtained from patients with prostate, colon, melanoma, lung, and breast cancer.

Growing Popularity of Prostate Liquid Biopsy

Prostate liquid biopsies are becoming increasingly common in the global prostate cancer biopsy market, which represents a significant shift towards non-invasive diagnostic techniques. Liquid biopsies provide a less invasive option than standard tissue biopsies by analyzing circulating tumor cells or bits of tumor DNA in a patient's blood. The approach is a desirable choice for patients and healthcare professionals because it greatly lowers patient suffering and the chance of problems. Liquid biopsies are becoming more widely accepted due to their ability to detect cancer early, track its course, and evaluate the effectiveness of treatment. The trend highlights the increasing need for better patient-friendly, precise, and effective diagnostic technologies in the management of prostate cancer, which is driving innovation in the global prostate cancer biopsy market.

PanGIA Biotech announced in January 2024 that it aims to develop scalable and real liquid biopsy technology for global impact. It has completed its prospective, multicenter, three-year clinical study on liquid biopsy for prostate cancer and the study was conducted prospectively. The news was announced as the business got ready to start more clinical trials with the PanGIA Liquid Biopsy Platform for early multi-cancer diagnosis.

North America Dominates the Market

The global prostate cancer biopsy market is dominated by North America, which is a result of several important factors. Firstly, the area is home to a highly developed healthcare infrastructure with a focus on cancer research and diagnostics, which is made possible by significant expenditure on medical technology. The population's high level of knowledge of prostate cancer and the value of early detection plays a significant role in the high demand for biopsy procedures.

Also, the strong regulatory environment and pro-innovation policies in healthcare in North America aid in the quick uptake of cutting-edge diagnostic tools like AI-enhanced imaging and MRI-guided biopsies. When assessed together, these factors guarantee North America's dominant position in the industry, propelling advancement and establishing global benchmarks for prostate cancer diagnosis.

Oxford BioDynamics, plc announced in September 2023 that its EpiSwitch Prostate Screening (PSE) blood test has been validated in its US clinical laboratory. It means men who are at risk of prostate cancer can immediately access their highly accurate PSE test.

Future Market Scenario (2024 - 2031F)

The global prostate cancer biopsy market is expected to be significantly impacted by the excessive adoption of AI tools. The market is to be benefited from the increasing accessibility of the technology in the future.

The rising demand for minimally invasive procedures, such as liquid biopsies, will significantly propel the growth of the market in the future. Liquid biopsy requires less time and delivers precise results.

The need for biopsy techniques and diagnostic technology may rise significantly in various countries in Asia, Africa, and Latin America due to rising access to healthcare facilities and upgrading healthcare infrastructure. The growth will positively impact the global prostate cancer biopsy market in the future.

Healthcare professionals are actively adopting numerous screening techniques like active surveillance and tailored screening which will boost the growth of the global prostate cancer biopsy market in the future.

Key Players Landscape and Outlook

Major firms in the global prostate cancer biopsy market are engaging in collaborations. It is a strategy that greatly boosts growth and innovation in the global prostate cancer biopsy market. Companies can make use of each other's advantages through these collaborations, which frequently involve sharing technology breakthroughs, research capacity, and market access. Partnerships may result in the creation of less intrusive, more precise biopsy technologies, improving patient care and diagnostic accuracy. To increase detection rates, technology businesses and biopharmaceutical companies should form partnerships to expedite the integration of AI and machine learning in biopsy analysis. In addition to advancing technology, these joint initiatives broaden the application of cutting-edge diagnostic tools and provide a cooperative yet competitive market environment that benefits patients everywhere.

Following the successful evaluation of a blood-based genomic profiling test in prostate cancer, MBdx and AstraZeneca extended their collaboration agreement in June 2023 to support the shift from tissue to liquid biopsy. With the help of the PROSPER 2.0 project's AlphaLiquid HRR test, patients with metastatic castration-resistant prostate cancer (mCRPC) now have a plethora of options.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Prostate Cancer Biopsy Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type
    • 4.2.1. Prostate Liquid Biopsy
    • 4.2.2. Prostate Needle Biopsy
  • 4.3. By Product
    • 4.3.1. Needles
    • 4.3.2. Kits and Trays
    • 4.3.3. Others
  • 4.4. By Guidance
    • 4.4.1. MRI-Guided Prostate Biopsy Devices
    • 4.4.2. CT-Guided Prostate Biopsy Devices
    • 4.4.3. Ultrasound-Guided Prostate Biopsy Devices
    • 4.4.4. Others
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Diagnostic Centers
    • 4.5.3. Others
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia-Pacific
    • 4.6.4. South America
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Prostate Cancer Biopsy Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type
      • 5.1.2.1. Prostate Liquid Biopsy
      • 5.1.2.2. Prostate Needle Biopsy
    • 5.1.3. By Product
      • 5.1.3.1. Needles
      • 5.1.3.2. Kits and Trays
      • 5.1.3.3. Others
    • 5.1.4. By Guidance
      • 5.1.4.1. MRI-Guided Prostate Biopsy Devices
      • 5.1.4.2. CT-Guided Prostate Biopsy Devices
      • 5.1.4.3. Ultrasound-Guided Prostate Biopsy Devices
      • 5.1.4.4. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Diagnostic Centers
      • 5.1.5.3. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Type
      • 5.1.6.2.1. Prostate Liquid Biopsy
      • 5.1.6.2.2. Prostate Needle Biopsy
      • 5.1.6.3. By Product
      • 5.1.6.3.1. Needles
      • 5.1.6.3.2. Kits and Trays
      • 5.1.6.3.3. Others
      • 5.1.6.4. By Guidance
      • 5.1.6.4.1. MRI-Guided Prostate Biopsy Devices
      • 5.1.6.4.2. CT-Guided Prostate Biopsy Devices
      • 5.1.6.4.3. Ultrasound-Guided Prostate Biopsy Devices
      • 5.1.6.4.4. Others
      • 5.1.6.5. By End-user
      • 5.1.6.5.1. Hospitals
      • 5.1.6.5.2. Diagnostic Centers
      • 5.1.6.5.3. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Product
  • 6.3. By Guidance
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Thermo Fisher Scientific Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Becton Dickinson and Company
  • 13.3. F. Hoffmann-La Roche Ltd.
  • 13.4. AstraZeneca plc
  • 13.5. Koninklijke Philips N.V.
  • 13.6. Biocept Inc
  • 13.7. Angle plc
  • 13.8. Eisai Co., Ltd.
  • 13.9. Onconetix, Inc.
  • 13.10. StageZero Life Sciences Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 5. Global Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 6. Global Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Prostate Cancer Biopsy Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 11. North America Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 12. North America Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 13. North America Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 18. United States Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 19. United States Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 20. United States Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 24. Canada Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 25. Canada Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 26. Canada Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 30. Mexico Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 31. Mexico Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 32. Mexico Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 36. Europe Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 37. Europe Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 38. Europe Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 43. Germany Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 44. Germany Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 45. Germany Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 49. France Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 50. France Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 51. France Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 55. Italy Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 56. Italy Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 57. Italy Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 61. United Kingdom Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 62. United Kingdom Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 63. United Kingdom Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 67. Russia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 68. Russia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 69. Russia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 73. Netherlands Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 74. Netherlands Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 75. Netherlands Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 79. Spain Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 80. Spain Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 81. Spain Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 85. Turkey Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 86. Turkey Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 87. Turkey Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 91. Poland Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 92. Poland Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 93. Poland Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 97. South America Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 98. South America Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 99. South America Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 104. Brazil Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 105. Brazil Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 106. Brazil Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 110. Argentina Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 111. Argentina Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 112. Argentina Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 116. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 117. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 118. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 120. India Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 123. India Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 124. India Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 125. India Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 129. China Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 130. China Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 131. China Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 135. Japan Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 136. Japan Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 137. Japan Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 141. Australia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 142. Australia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 143. Australia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 147. Vietnam Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 148. Vietnam Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 149. Vietnam Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 153. South Korea Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 154. South Korea Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 155. South Korea Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 159. Indonesia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 160. Indonesia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 161. Indonesia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 165. Philippines Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 166. Philippines Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 167. Philippines Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 171. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 172. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 173. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 178. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 179. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 180. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 184. UAE Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 185. UAE Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 186. UAE Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 190. South Africa Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 191. South Africa Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 192. South Africa Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Guidance Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023